Promising Expansion in Rheumatoid Arthritis Drives Buy Rating for Spyre Therapeutics
BTIG analyst Julian Harrison has maintained their bullish stance on SYRE stock, giving a Buy rating on January 14.Invest with Confidence: ...
BioXcel Therapeutics expands board, appoints new director
BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a pharmaceutical company specializing in drug development with a current market ...
Business Insider11d
Nektar Therapeutics: Promising Drug Pipeline and Strategic Expansion Drive Buy Rating
Analyst Arthur He CFA of H.C. Wainwright maintained a Buy rating on Nektar Therapeutics (NKTR – Research Report), retaining the price target of $6.50. Discover outperforming stocks and invest ...
Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications
NDAQ:HOTH) Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications ...